SANUWAVE Health Lowers Q2 Revenue Guidance Due to Market Disruption
SNWV is trading near its 52-week low of $14.11 (15% below the low).
Summary
SANUWAVE Health cut its Q2 revenue guidance, citing market disruption from CMS reimbursement clawbacks and increased competition from used Ultramist systems, sending the stock below its 52-week low.
Key Events · Earnings and Guidance · SNWV
-
Q2 Revenue Guidance Lowered
SANUWAVE Health now expects Q2 2026 revenues to be between $8.5 million and $9.5 million, a reduction from prior guidance.
-
Market Disruption Impacts Sales
The company attributes the lowered guidance to material changes in the capital equipment market for its Ultramist system, specifically citing widespread CMS reimbursement clawbacks.
-
Used Systems Cannibalize New Sales
Closures of wound care practices due to reimbursement issues are leading to a secondary market for used Ultramist systems, which is significantly impacting new system sales.
-
Consumables Volume Remains Robust
Despite challenges in capital equipment sales, the company is on pace for record quarterly unit volume of applicator (consumables) shipments in Q2.
Analysis · SNWV · Industrial Applications And Services
SANUWAVE Health has reduced its second-quarter 2026 revenue guidance to $8.5-$9.5 million, down from previous expectations. This revision is primarily driven by significant market disruption in the capital equipment market for its Ultramist system. The company cites widespread clawbacks of CMS reimbursement for advanced wound care products, leading to wound care practice closures and a surge of used Ultramist systems cannibalizing new sales. This negative news comes as the stock trades below its 52-week low, highlighting increased pressure. While applicator volumes remain strong, the challenges in capital equipment sales present a near-term headwind.
At the time of this filing, SNWV was trading at $11.99 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $126.1M. The 52-week trading range was $14.11 to $46.59. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.